Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00807885 · ClinicalTrials.gov registry record · Phase 4
Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase
A Phase 4 study, sponsored by Baxter Healthcare Corporation.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT00807885 is a Phase 4 study that has completed, run by Baxter Healthcare Corporation. The registered enrollment target is 100 participants.
The verdict
NCT00807885, a Phase 4 study, has completed, sponsored by Baxter Healthcare Corporation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose is to evaluate the ease of use and technical challenges encountered during subcutaneous infusion of Lactated Ringer's (LR) solution, preceded by recombinant human hyaluronidase (hylenex), utilizing commonly used angiocatheter gauges and button delivery systems. The safety and tolerability of hylenex-augmented SC infusion of LR through these delivery systems is also being evaluated.
Interventions
- DRUG hylenex-facilitated subcutaneous Lactated Ringer's infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00807885
The ClinicalTrials.gov registry entry for NCT00807885 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxter Healthcare Corporation, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which hylenex-facilitated subcutaneous Lactated Ringer's infusion is the first listed.
NCT00807885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00807885 about?
NCT00807885 is a clinical study titled "Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase". The purpose is to evaluate the ease of use and technical challenges encountered during subcutaneous infusion of Lactated Ringer's (LR) solution, preceded by recombinant human hyaluronidase (hylenex), utilizing commonly used angiocatheter gauges and button delivery systems. The safety and tolerabilit...
What is the current status of trial NCT00807885?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2008-12. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00807885?
The interventions under investigation include: hylenex-facilitated subcutaneous Lactated Ringer's infusion (DRUG).
Who is sponsoring clinical trial NCT00807885?
This trial is sponsored by Baxter Healthcare Corporation, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.